STOCK TITAN

ALEC Form 144 Filed for 5,717-Share Sale from RSU Vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Alector, Inc. (ALEC) Form 144 shows a proposed sale of 5,717 shares of common stock through Morgan Stanley Smith Barney on 09/02/2025 with an aggregate market value of $13,434.95. The shares were acquired by vesting of restricted stock units on 08/29/2025 totaling 11,257 units, with payment/settlement dated 08/29/2025. The filer previously sold 6,034 shares on 06/02/2025 for gross proceeds of $8,075.91. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.

Positive

  • Disclosure compliance: Form 144 submitted with required sale and acquisition details
  • Proceeds sourced from RSU vesting: shares to be sold were acquired through vesting on 08/29/2025

Negative

  • Insider selling shares: Proposed sale of 5,717 shares (though small relative to 101,212,329 outstanding)

Insights

TL;DR: Small insider sale arising from RSU vesting; amount is immaterial relative to shares outstanding.

The proposed sale of 5,717 shares stems from RSU vesting on 08/29/2025 and will be executed via Morgan Stanley Smith Barney on 09/02/2025. With 101,212,329 shares outstanding, the shares to be sold represent approximately 0.0056% of the outstanding common stock, indicating the transaction is likely routine compensation monetization rather than a major change in insider ownership. Prior sale on 06/02/2025 of 6,034 shares for $8,075.91 is disclosed, showing prior liquidity events by the same person. No information in the filing indicates undisclosed material developments at the company.

TL;DR: Filing appears to meet Rule 144 disclosure requirements and includes standard seller representations.

The form provides required details: class of security, broker, number of shares, aggregate value, acquisition method (vesting of RSUs), and prior sales in the past three months. The notice contains the seller's representation regarding absence of undisclosed material adverse information. The filing does not state a 10b5-1 plan adoption date or other trading-plan details, so no affirmative claim of a pre-arranged trading plan is evident in the form content.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Alector's (ALEC) Form 144 report?

The form reports a proposed sale of 5,717 common shares via Morgan Stanley Smith Barney on 09/02/2025 with aggregate market value $13,434.95.

How were the shares being sold acquired?

The shares were acquired on 08/29/2025 by the vesting of restricted stock units, totaling 11,257 securities acquired on that date.

Has the seller sold other Alector shares recently?

Yes, the filing discloses a prior sale of 6,034 shares on 06/02/2025 for gross proceeds of $8,075.91.

What broker will execute the sale?

The sale is to be executed through Morgan Stanley Smith Barney LLC Executive Services on the Nasdaq exchange.

What representation does the seller make about material information?

By signing, the seller represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
Alector

NASDAQ:ALEC

View ALEC Stock Overview

ALEC Rankings

ALEC Latest News

ALEC Latest SEC Filings

ALEC Stock Data

265.97M
95.26M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
SOUTH SAN FRANCISCO